Teva's Restructuring Plan

Background

Kåre Schultz was appointed as Teva’s (NYSE:TEVA) CEO in September 2017 at the time when Teva has been suffering from Copaxone competition, U.S. generics margin erosion as well as a vacuum of credible leadership.

Schultz was not the Board’s first choice. However, the Lundbeck’s (OTC:HLUKF) (OTCPK:HLUYY) turnaround story with the stock value tripling within two years was too hard to ignore. Lundbeck's president and CEO has been the president and COO of Novo Nordisk A/S (NYSE:NVO) since January 2014. He joined Novo Nordisk in 1989. Schultz has an MSc in Economics from the University of Copenhagen, Denmark, from 1987. He is a Danish national, born in 1961.

Last month, Teva’s new CEO, Kåre Schultz, took the helm and promised major restructuring changes. Furthermore, on 12.14.2017, Teva announced its new strategy going forward, that included:

READ FULL ARTICLE HERE